Response to: ‘TARA Study: a new perspective on tapering drugs in RA’ by Mishra et al

We are pleased about the interest in our article by Mishra et al and we would like to respond to their questions so that there can be no ambiguity.1 2 First of all, there is some clarification needed on the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) that were used in combination with the TNF-inhibitors at baseline in the TApering strategies in Rheumatoid Arthritis (TARA) study. In table 1, we elaborate on the...